As per the agreement, Fina will earn upfront payment, payments based on achievement of Chinese regulatory milestones, and royalty payments that are contingent upon successful development and commercialization.
Fina Biosolutions CEO and scientific director Andrew Lees said, "Our expertise in bioconjugation allows vaccines to be manufactured at lower costs than traditional methods, which ultimately allows for greater uptake into developing economies and in turn benefits all of humanity."
The agreement also includes process development, personnel training at Fina BioSolutions labs in Rockville, MD and scalable manufacturing of conjugate vaccines at CDIBP.
The technology is proven in marketed vaccines Synflorix, Menitorix, Nimenrix and sold by GlaxoSmithKline, according to CDIBP.